LONDON --(BUSINESS WIRE)--Mar. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time ( 8 a.m. Eastern Time ).
LONDON --(BUSINESS WIRE)--Mar. 20, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude
LONDON --(BUSINESS WIRE)--Mar. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to persons
LONDON --(BUSINESS WIRE)--Mar. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably
LONDON --(BUSINESS WIRE)--Mar. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida .
LONDON --(BUSINESS WIRE)--Feb. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights 1 Fourth-quarter revenue of $310.1 million
William Kozy will remain Board Chair LONDON --(BUSINESS WIRE)--Feb. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of
Move Reinforces Focus on Core Cardiopulmonary and Neuromodulation Businesses ACS Standalone Cannulae Products and Accessories to Transition Into Cardiopulmonary Business Unit LONDON --(BUSINESS WIRE)--Jan. 8, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today
LONDON --(BUSINESS WIRE)--Jan. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time ( 8 a.m. Eastern Time ).
